Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage

• Published in: Nature communications Vol. 15; no. 1; pp. 8550 - 12
• Main Authors: Lewnard, Joseph A., Mahale, Parag, Malden, Debbie, Hong, Vennis, Ackerson, Bradley K., Lewin, Bruno J., Link-Gelles, Ruth, Feldstein, Leora R., Lipsitch, Marc, Tartof, Sara Y.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.10.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326/596/4130; 692/308/174; 692/699/255/2514; Adult; Aged; Clinical outcomes; COVID-19; COVID-19 - epidemiology; COVID-19 - immunology; COVID-19 - virology; COVID-19 vaccines; COVID-19 Vaccines - immunology; Disease transmission; Electronic health records; Electronic medical records; Emergency medical care; Emergency medical services; Emergency response; Epidemiology; Female; Hospitalization - statistics & numerical data; Humanities and Social Sciences; Humans; Immune Evasion; Infections; Male; Middle Aged; multidisciplinary; SARS-CoV-2 - immunology; Science; Science (multidisciplinary); Sensitivity analysis; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; United States - epidemiology; Viral diseases; United States; United States > US
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-024-52668-w

The SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023–24. However, this surge in infections was not accompanied by COVID-19 hospitalizations and mortality commensurate with prior waves. To understand shifts in COVID-19 epidemiology associated with JN.1 emergence, we compared characteristics and clinical outcomes of time-matched cases infected with BA.2.86 lineages (predominantly representing JN.1) versus co-circulating XBB-derived lineages in December, 2023 and January, 2024. Cases infected with BA.2.86 lineages received greater numbers of COVID-19 vaccine doses, including XBB.1.5-targeted boosters, in comparison to cases infected with XBB-derived lineages. Additionally, cases infected with BA.2.86 lineages experienced greater numbers of documented prior SARS-CoV-2 infections. Cases infected with BA.2.86 lineages also experienced lower risk of progression to severe clinical outcomes requiring emergency department consultations or hospital admission. Sensitivity analyses suggested under-ascertainment of prior infections could not explain this apparent attenuation of severity. Our findings implicate escape from immunity acquired from prior vaccination or infection in the emergence of the JN.1 lineage and suggest infections with this lineage are less likely to experience clinically-severe disease. Monitoring of immune escape and clinical severity in emerging SARS-CoV-2 variants remains a priority to inform responses. The SARS-CoV-2 JN.1 lineage spread rapidly in winter 2023-24 with high estimated levels of transmission but limited increase in severe disease burden. Here, the authors use electronic health record data from the United States to investigate the immune history and clinical outcomes of patients infected with this strain.